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EaBACKGROUND Infections are the most common noncardiac complication after cardiac surgery, but their incidence
across a broad range of operations, as well as the management factors that shape infection risk, remain unknown.
OBJECTIVES This study sought to prospectively examine the frequency of post-operative infections and associated
mortality, and modiﬁable management practices predictive of infections within 65 days from cardiac surgery.
METHODS This study enrolled 5,158 patients and analyzed independently adjudicated infections using a competing
risk model (with death as the competing event).
RESULTS Nearly 5% of patients experienced major infections. Baseline characteristics associated with increased
infection risk included chronic lung disease (hazard ratio [HR]: 1.66; 95% conﬁdence interval [CI]: 1.21 to 2.26), heart
failure (HR: 1.47; 95% CI: 1.11 to 1.95), and longer surgery (HR: 1.31; 95% CI: 1.21 to 1.41). Practices associated with
reduced infection risk included prophylaxis with second-generation cephalosporins (HR: 0.70; 95% CI: 0.52 to 0.94),
whereas post-operative antibiotic duration >48 h (HR: 1.92; 95% CI: 1.28 to 2.88), stress hyperglycemia (HR: 1.32; 95%
CI: 1.01 to 1.73); intubation time of 24 to 48 h (HR: 1.49; 95% CI: 1.04 to 2.14); and ventilation >48 h (HR: 2.45; 95% CI:
1.66 to 3.63) were associated with increased risk. HRs for infection were similar with either <24 h or <48 h of antibiotic
prophylaxis. There was a signiﬁcant but differential effect of transfusion by surgery type (excluding left ventricular assist
device procedures/transplant) (HR: 1.13; 95% CI: 1.07 to 1.20). Major infections substantially increased mortality (HR:
10.02; 95% CI: 6.12 to 16.39).
CONCLUSIONS Major infections dramatically affect survival and readmissions. Second-generation cephalosporins
were strongly associated with reduced major infection risk, but optimal duration of antibiotic prophylaxis requires
further study. Given practice variations, considerable opportunities exist for improving outcomes and preventing
readmissions. (Management Practices and Risk of Infection Following Cardiac Surgery; NCT01089712) (J Am Coll
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373ABB R E V I A T I O N S
AND ACRONYMS
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
CTSN = Cardiothoracic Surgical
Trials Network
HR = hazard ratio
ICU = intensive care unit
LVAD = left ventricular assist
device
QI = quality improvement
RBC = red blood cell
SCIP = Surgical Care
Improvement Project
SSI = surgical site infectionH ealthcare-acquired infections, many ofwhich are preventable, are extraordinarilyimportant. An estimated 1.7 million indi-
viduals acquire an infection while hospitalized,
resulting in 100,000 deaths annually and $6.5 billion
in additional health care expenditures (1). This recog-
nition has galvanized quality improvement (QI) ef-
forts involving clinicians and policymakers alike,
leading to important progress in several areas, such
as catheter-related bloodstream infections in inten-
sive care units (ICUs) (2). Such rigorous QI efforts
have not been applied uniformly to cardiac surgical
patients, an increasingly vulnerable and elderly pop-
ulation with multiple comorbidities. Beyond the risk
for catheter-related infections that are common in
the ICU environment, the surgical setting presentsSEE PAGE 382 STS = Society of Thoracic
Surgeonsadditional risks related to prolonged mechanical
ventilation, extensive blood product usage,
indwelling catheter drainage, and open cavities.
Studies of patients undergoing cardiac surgery
typically focus on a subset of infections (most no-
tably, deep sternal site infections), primarily address
coronary artery bypass grafting (CABG) rather than
the broad range of commonly performed cardiac
surgical procedures, capture events only during the
in-hospital perioperative period, and rely on volun-
tary reporting (3,4). Moreover, although the literature
has examined the relationship between several
management practices and post-operative infection
risk (2,5,6), many questions about the development of
effective preventive strategies remain unanswered.
Such information is especially timely, given the de-
cision by the U.S. Centers for Medicare and Medicaid
Services to withhold reimbursement for care related
to some preventable complications, including several
healthcare-acquired infections. In addition, the U.S.
Centers for Medicare and Medicaid Services has
endorsed performance measures developed by the
Surgical Care Improvement Project (SCIP), which
include choice of antibiotics and control of early post-
operative blood glucose level (7).
The Cardiothoracic Surgical Trials Network (CTSN)
has addressed these issues by conducting a uniqueyyyCardiovascular Division, Brigham and Women’s Hospital, Boston, Massach
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to investigate frequency of post-operative
infections, their microbiology, and associ-
ated mortality and identify modiﬁable
management practices associated with post-
operative infections within 65 days from
index surgery.
METHODS
PARTICIPANTS. The study population in-
cludes all patients at the 10 CTSN core site
with a clinical indication for cardiac surgery,
without an active systemic infection, and at
age $18 years of age. The study received
Institutional Review Board approval, and all
patients provided written informed consent.
DESIGN. For this study, we assumed that the
60-day incidence of major infections was
approximately 4% to 5% (3,4). We targeted a mini-
mum sample size of 5,000 patients to obtain at least
200 patients with major infections. This sample size
was based not on explicit statistical criteria, but on
acquiring an adequate number of events (at least 10
per variable) to ensure stability of coefﬁcient esti-
mates in our models (8,9). Patients were followed for
up to 65 days after surgery with 2 planned post-
discharge assessments at 30 and 60 days after sur-
gery; the last date of follow-up was November 29,
2010 (Online Fig. 1). Data were transmitted elec-
tronically to the data coordinating center, which
conducted electronic monitoring and sent monitors
to the sites to review data quality (Online Table 1).
An independent event adjudication committee con-
sisting of 3 infectious disease physicians reviewed all
major infections and organisms. The ﬁnal date of
event adjudication was in June 2011.
ENDPOINTS, PATIENT AND CLINICAL CHARACTERISTICS.
The primary endpoint was major infection within
65 days of the index cardiac surgery. The 10 major
infections included were deep incisional surgical
site infection occurring at the primary chest inci-
sion, deep incisional surgical site infection (SSI)
occurring at a secondary incision site (e.g., saphenous
harvest and groin cannulation sites), mediastinitis,usetts. The research was supported by the National
isorders and Stroke (Grant no. 7U01 HL088942), and
ber of the Research Council of InHealth in 2010 and
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374infectious myocarditis or pericarditis, endocarditis,
cardiac device infection, pneumonia, empyema,
Clostridium difﬁcile colitis, and bloodstream infec-
tion. Secondary endpoints included the following
minor infections: primary and secondary superﬁcial
incisional surgical site infections, symptomatic uri-
nary tract infections, and asymptomatic bacteriuria.
Infections were classiﬁed on the basis of deﬁnitionsTABLE 1 Patient and Operative Characteristics and Unadjusted Risk R
Infected
(n ¼ 237)
Not Infect
(n ¼ 4,92
Demographics
Age, yrs 65.6  13.8 64.3  13
Male 157 (66.2) 3,293 (66
White 181 (76.4) 4,141 (84
BMI 28.5 (24.4–33.2) 28.2 (25.1–3
Insurance
Medicaid 14 (5.9) 219 (4.5
Medicare 103 (43.5) 1,825 (37
Government (other) 20 (8.4) 606 (12.
Private 87 (36.7) 2,012 (41
None/self 13 (5.5) 247 (5.0
Baseline laboratories
WBC,  103/ml 7.2 (5.8–8.7) 6.9 (5.7–8
Creatinine, mg/dl 1.1 (0.9–1.4) 1.0 (0.8–1
Hemoglobin, g/dl 12.5 (11.0–13.9) 13.4 (12.1–1
Cardiac morbidity
Heart failure 110 (46.4) 1,395 (28
Ejection fraction 50.0 (35.0–60.0) 55.0 (49.0–6
Previous cardiac surgery 74 (31.2) 884 (18.0
Noncardiac morbidity
Diabetes† 66 (27.9) 1,103 (22
COPD
None 178 (75.1) 4,234 (86
Mild or moderate 47 (19.8) 597 (12.1
Severe 12 (5.1) 90 (1.8
Operative
Surgery time, h 4.8 (3.9–6.4) 4.2 (3.3–5
Bypass time, min‡ 129.0 (94.0–180.0) 104.0 (77.0–
Sternotomy 218 (92.0) 4,451 (90
Surgery type
Elective 155 (65.4) 3,651 (74
Urgent 72 (30.4) 1,142 (23.
Emergent 10 (4.2) 128 (2.6
Procedure
Isolated CABG 54 (22.8) 1,623 (33.
Isolated valve 72 (30.4) 1,806 (36
CABG þ valve 39 (16.5) 653 (13.3
LVAD/Tx 29 (12.2) 93 (1.9)
Thoracic aortic 23 (9.7) 405 (8.2
Other§ 20 (8.4) 341 (6.9
Values are mean  SD, n (%), or median (interquartile range). *Based on Cox proportional
characteristic. †Insulin or oral medications. ‡A total of 91.1% of patients had on-pump
aneurysmectomies, patent foramen ovale closures, ablations, septal myectomies, excisio
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obst
or transplant surgery; WBC ¼ white blood cell.from the Centers for Disease Control and Prevention
and the National Healthcare Safety Network surveil-
lance (Online Appendix) (10). Other secondary end-
points included all-cause mortality, reoperation, and
hospital readmission.
We collected data on patient characteristics (de-
mographics, baseline laboratory values, comorbid-
ities), surgery-related factors (e.g., prior intra-aorticatios (Major Infection)
ed
1)
Overall
(n ¼ 5,158) Unadjusted HR p Value*
.2 64.4  13.2 1.01 0.13
.9) 3,450 (66.9) 0.97 0.81
.2) 4,322 (83.9) 0.61 0.001
2.2) 28.2 (25.1–32.3) 1.01 0.34
0.11
) 233 (4.5) 1.90
.2) 1,928 (37.5) 1.69
3) 626 (12.2) 1.00 (ref)
.0) 2,099 (40.8) 1.30
) 260 (5.1) 1.58
.4) 7.0 (5.7–8.4) 1.03 0.11
.2) 1.0 (0.8–1.2) 1.18 <0.001
4.6) 13.4 (12.0–14.5) 0.80 <0.001
.4) 1,505 (29.2) 2.16 <0.001
0.0) 55.0 (48.0–60.0) 0.97 <0.001
) 958 (18.6) 2.03 <0.001
.4) 1,169 (22.7) 1.33 0.05
<0.001
.0) 4,412 (85.5) 1.00 (ref)
) 644 (12.5) 1.84
) 102 (2.0) 3.04
.2) 4.2 (3.3–5.2) 1.38 <0.001
138.0) 105.0 (78.0–140.0) 1.01 <0.001
.5) 4,669 (90.5) 1.20 0.45
0.01
.2) 3,806 (73.8) 1.00 (ref)
2) 1,214 (23.5) 1.47
) 138 (2.7) 1.82
<0.001
0) 1,677 (32.5) 1.00 (ref)
.7) 1,878 (36.4) 1.20
) 692 (13.4) 1.79
122 (2.4) 8.07
) 428 (8.3) 1.72
) 361 (7.0) 1.75
hazards model where outcome is time to infection and predictor is baseline or patient
surgical procedures. §Ventricular septal defect repairs, atrial septal defect repairs,
n of cardiac tumors, pericardiectomies, and limited other procedures.
ructive pulmonary disease; HR ¼ hazard ratio; LVAD/Tx ¼ left ventricular assist device
TABLE 2 Frequency, Type, and Timing of Infection
Type of Infection
Number of
Events
Number of
Patients
Percent of
Patients
(n ¼ 5,158)
Days From Surgery
to First Infection
Median Minimum Maximum
Pneumonia 125 123 2.38 8 1 62
Bloodstream infection 59 56 1.09 15 0 65
C. difﬁcile colitis 52 50 0.97 17 3 63
Deep incision surgical site
infection (chest)*
26 26 0.56 20.5 5 54
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375balloon pump, ventricular assist device therapy,
and surgery time), and management practices (e.g.,
antimicrobial prophylaxis, glycemic control, and line
management).
STATISTICAL ANALYSIS. We used time-to-event
analysis to assess the association of patient- and
procedure-related variables and process of care vari-
ables on occurrence of post-operative infection.
Crude risk ratios describe univariate associations be-
tween these variables and ﬁrst major infection.
To account for the effect of mortality on infec-
tion risk in the multivariable analysis, we ﬁtted
competing risk models with death and infection as
competing events (11). We ﬁt multivariable models
for infection in 2 stages. First, we used proportional
hazards regression to select a set of patient- and
procedure-related risk factors associated (at p < 0.05)
with time to onset of major infection, considering
mortality as a competing risk. Second, we assessed
the additional contribution of management practices
utilized prior to the ﬁrst infection. One exception is
post-operative transfusions, where the timing was
not always available. At each stage, removal of sta-
tistically non-signiﬁcant variables, reﬁtting, and
retesting was continued until all variables in the
model had a p value of #0.05. All patient- and
procedure-speciﬁc variables selected in the ﬁrst
stage were kept in the second-stage model. We also
analyzed the association of type and duration of
antibiotics and infection type, adjusting for baseline
characteristics. Interactions were tested between
surgery type and management practices included in
the second-stage model.
For the analysis of mortality we used proportional
hazard models, with infection treated as a time-
dependent variable. We used a stepwise selection
process; the ﬁnal model included only variables that
had a p value <0.05. All models were tested for the
assumption of proportional hazards. All analyses
utilized SAS statistical software (version 9.2, Cary,
North Carolina), and R 2.15 (R Development Core
Team).Mediastinitis 12 12 0.23 24.5 6 60
Deep incision surgical site
infection (groin)*
10 10 0.21 26 6 49
Myocarditis or
pericarditis
5 4 0.08 16 14 27
Empyema 4 3 0.06 56 13 63
Endocarditis 3 3 0.06 25 25 51
Device-related percut
site infection
3 3 0.06 54 9 62
Pocket infection† 2 2 2.33 38.5 15 62
*Denominator for patients with a deep surgical site infection is patients having a sternotomy (n ¼ 4,669).
†Denominator for pocket infection is patients who had left ventricular assist device placed, replaced, or removed
for heart transplant (n ¼ 86).RESULTS
PATIENTS. Between February and October 2010, 10
academic cardiac surgery programs enrolled 5,158
patients, with a mean age of 64  13 years and a
median body mass index of 28.2 (interquartile range:
25.1 to 32.3) kg/m2 (Table 1). Diabetes mellitus was
present in 1,169 (23%) patients, heart failure in 1,505
(29%), and chronic lung disease in 746 (14%), and
958 (19%) had prior cardiac surgery. The mostfrequently performed procedures were isolated
CABG (1,677; 33%), isolated valve (1,878; 36%), and
combined CABG and valve surgery (692; 13%), with
3,806 (74%) of all procedures being elective. Median
cardiopulmonary bypass time was 105 min (inter-
quartile range: 78 to 140 min).
FREQUENCY AND CHARACTERISTICS OF INFECTIONS.
A total of 237 patients (4.6%) experienced 301 major
infections (rate/patient month: 0.028; Online
Table 2 for risk by procedure type), most commonly
pneumonia, bloodstream infections, and C. difﬁcile
colitis (Table 2). Median time to ﬁrst major infection
was 13 days (interquartile range: 6 to 25 days); 134
(45%) occurred after hospital discharge, predomi-
nantly deep SSIs, endocarditis, and device-related
percutaneous site infection. Pneumonia and blood-
stream infections occurred more commonly during
the index hospitalization, while C. difﬁcile colitis
occurred equally before and after discharge.
C. difﬁcile infections were the primary post-operative
infection for 40 (80%) patients. The incidence of
C. difﬁcile infections did not vary with age in this
older population, but left ventricular assist device
(LVAD)/transplant patients had a higher risk than
other cardiac surgery patients. Eight percent of pa-
tients experienced minor infections (Online Table 3),
the most prevalent being symptomatic urinary tract
infections (174; 3.4%) and superﬁcial incision site
infection (137; 2.7%).
Positive microbial isolates were identiﬁed for
230 (76%) of major infections; 85 (32%) were
TABLE 3 Organisms
Pneumonia
Gram-positive bacteria 12.6
Staphylococcus aureus 9.5
Meth resistant (44%)
Streptococcus sp 3.2
Gram-negative bacteria 82.1
Enterobacteriaceae 43.2
Pseudomonas 15.8
Other healthcare GNR* 13.7
Serratia marcescens 6.3
H. inﬂuenzae 3.2
Other 5.3
BSI
Gram-positive bacteria 47.5
Staphylococcus aureus 13.1
Meth resistant (38%)
Staphylococcus Epi 9.8
Meth resistant (50%)
Enterococcus 11.5
Fungi (Candida) 9.8
Streptococcus sp 1.6
Staph hominis (coagulase negative) 1.6
Gram-negative bacteria 47.5
Enterobacteriaceae 29.5
Serratia marcescens 8.2
Other healthcare GNR* 4.9
Pseudomonas 3.3
Anaerobe (Bact. fragilis) 1.6
Other 4.9
Mediastinitis
Gram-positive bacteria 61.5
Staphylococcus aureus 46.2
Meth resistant (33%)
Staphylococcus Epi 7.7
Meth resistant (100%)
Fungi (Candida) 7.7
Gram-negative bacteria 38.5
Enterobacteriaceae 15.4
Pseudomonas 7.7
Other healthcare GNR* 7.7
Other (Unidentiﬁed) 7.7
C. difﬁcile colitis
Clostridium difﬁcile 100.0
Continued in the next column
TABLE 3 Continued
Endocarditis
Gram-positive bacteria 100.0
Staphylococcus aureus 66.7
Meth resistant (50%)
Staphylococcus hominis 33.3
Empyema
Gram-positive bacteria 60.0
Staphylococcus aureus 60.0
Meth resistant (67%)
Gram-negative bacteria 20.0
Pseudomonas 20.0
Other 20.0
SSI
Gram-positive bacteria 62.9
Staphylococcus aureus 40.0
Meth resistant (50%)
Staphylococcus Epi 14.3
Meth resistant (80%)
Enterococcus 5.7
Fungi (Candida) 2.9
Gram-negative bacteria 28.6
Enterobacteriaceae 17.1
Pseudomonas 5.7
Other healthcare GNR* 2.9
Other (Unidentiﬁed) 2.9
Other 8.6
Myocarditis/Pericarditis
Gram-positive bacteria 100.0
Streptococcus sp 50.0
Enterococcus 25.0
Fungi (Candida) 25.0
Pocket infection
Gram-positive bacteria 100.0
Staphylococcus aureus 66.7
Meth resistant (50%)
Fungi (Candida) 33.3
Cardiac device
Gram-positive bacteria 50.0
Staphylococcus Epi 50.0
Meth resistant (0%)
Gram-negative bacteria 50.0
Pseudomonas 50.0
Values are %. *Other healthcare gram negative rods: Acinetobacter,
Stenotrophomonas, Achromobacter, and Burkholderia.
BSI ¼ bloodstream infections; Epi ¼ epidermidis; Meth ¼ methicillin;
sp ¼ species; SSI ¼ surgical site infections.
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376Gram-positive, and 123 (47%) were Gram-negative.
Table 3 depicts the organism distribution for each
infection type.
RISK FACTORS FOR MAJOR INFECTION. Patient and
operative procedure characteristics associated with
increased risk of major infections were chronic lung
disease, heart failure, elevated creatinine, use of
corticosteroids, LVAD and transplant surgery, leaving
an open sternum for secondary closure and longer
surgery time (Table 4). Higher hemoglobin levels were
protective.There was substantial variation in management
practices; Table 5 shows frequency of use and their
association with infection (univariate analysis).
Close to 50% (2,427) of patients received nasal
decontamination, predominantly with mupirocin,
with variation not at the individual physician level,
but rather at the institutional level. Nearly all pa-
tients received appropriate surgical site hair removal
or did not require hair removal (a SCIP measure).
TABLE 4 Baseline and Procedure Characteristics Associated
With Infection
Baseline Variable HR (95% CI) p Value
COPD (yes/no) 1.66 (1.21–2.26) 0.002
Heart failure (yes/no) 1.47 (1.11–1.95) 0.007
Corticosteroids (yes/no) 1.91 (1.19–3.05) 0.007
Creatinine, mg/dl 1.15 (1.08–1.22) <0.001
Hemoglobin, g/dl 0.90 (0.84–0.97) 0.008
LVAD/Tx (yes/no) 2.89 (1.86–4.50) <0.001
Open sternum (yes/no) 6.35 (2.62–15.38) <0.001
Duration of surgery, h 1.31 (1.21–1.41) <0.001
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
TABLE 5 Management Practices and Unadjusted Risk Ratios (Major I
Variable n (%)
Nasal decontamination (yes/no) 2,427 (4
Hair removal (males only)
Shaving 108 (3
Clipping, depilatory cream, no hair removal 3,342 (9
Scrubbing surgical site
Chlorhexidine preparations 4,148 (8
Iodophors, alcohol, soap and water, other 933 (18
Central lines
More than 1 (vs. #1 line)† 542 (10
Femoral (vs. no femoral line)† 37 (0
Appropriate timing of pre-operative antibiotics (yes/no)‡ 4,422 (8
Intraoperative antibiotic redosed after 6 h (yes/no) 5,034 (9
Type of perioperative antibiotics
Second-generation cephalosporins 2,405 (4
First-generation cephalosporins, vancomycin, other 2,753 (5
Post-operative antibiotic duration†
0–24 h 2,599 (5
24–48 h 2,126 (4
>48 h 433 (8
Packed red blood cells, unit§ 3 (2
Venue of urinary catheter insertion
Bedside/other hospital 65 (1.
Operating room 5,075 (9
Nasogastric tube used (yes/no) 3,749 (7
Glucose management (ﬁrst 48 h after surgery)†
Hyperglycemic episode (>180 mg/dl) 2,228 (4
No hyperglycemic episode (#180 mg/dl) 2,923 (5
Mechanical ventilation†
#24 h 4,084 (7
24–48 h 683 (13
>48 h 387 (7
Elevation of head of bed (yes/no) 5,139 (9
Routine aspiration of secretions (yes/no) 4,955 (9
*Hazard ratio (HR): for glucose management adjusted for diabetes. †Frequency (%) not a
38 (0.74%); post-operative antibiotic duration: 0–24 h, 2,596 (50.3%); 24–48 h, 2,120 (
hyperglycemia, 2,925 (56.8%); mechanical ventilation: #24 h, 4,067 (78.9%); 24–48 h,
vancomycin). §48.1% patients received packed red blood cell transfusion.
CI ¼ conﬁdence interval.
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377Most patients (4,148; 82%) were scrubbed with
chlorhexidine preparations, and 11% (542) of patients
had more than 1 central line simultaneously placed
prior to ﬁrst infection. Eighty-six percent (4,422) of
patients received prophylactic antibiotics according
to the SCIP measure (<1 h prior to incision, and <2 h
if receiving vancomycin), but virtually all patients
undergoing longer procedures (i.e., after 6 h) were
redosed intra-operatively. Pre-operative antibiotics
administered included second-generation cephalo-
sporins ( vancomycin; 2,245; 44%), ﬁrst-generation
cephalosporins ( vancomycin; 1,859; 36%), and
vancomycin alone (967; 19%). Distribution of post-
operative antibiotics resembled pre-operative use;nfection)
Infection Rate Unadjusted HR* 95% CI
7.1) 0.023 0.80 0.61–1.03
.1) 0.013 0.60 0.19–1.87
6.9) 0.028 1.00 (ref)
1.6) 0.029 1.36 0.94–1.97
.4) 0.021 1.00 (ref)
.5) 0.051 2.06 1.49–2.85
.72) 0.166 5.63 2.78–11.39
6.4) 0.028 0.97 0.67–1.40
7.6) 0.026 0.41 0.23–0.71
6.6) 0.020 0.64 0.49–0.83
3.4) 0.034 1.00 (ref)
0.4) 0.020 1.14 0.83–1.55
1.2) 0.020 1.00 (ref)
.4) 0.113 5.90 4.25–8.19
–5) 0.043 1.29 1.24–1.33
3) 0.089 1.00 (ref)
8.7) 0.027 0.28 0.15–0.52
2.7) 0.023 1.20 0.89–1.62
3.3) 0.037 1.78 1.35–2.33
6.8) 0.020 1.00 (ref)
9.2) 0.015 1.00 (ref)
.3) 0.049 2.69 1.92–3.76
.5) 0.117 7.74 5.77–10.39
9.7) 0.027 0.35 0.09–1.42
6.1) 0.028 3.21 1.03–10.02
ccounting for timing of infection: more than 1 central line, 556 (10.8%); femoral line,
41.1%); >48 h, 442 (8.6%); glucose management: hyperglycemia, 2,229 (43.3%); no
670 (13.0%); >48 h, 417 (8.1%). ‡Within 1 h prior to surgical incision (2 h if receiving
TABLE 6 Process of Care Variables Associated With Infection
Process of Care Variables* HR (95% CI) p Value
Second-generation CEPH (yes/no) 0.70 (0.52–0.94) 0.02
Post-operative antibiotics (vs. 24–48 h)
0–24 h 1.00 (0.72–1.38) 0.98
>48 h 1.92 (1.28–2.88) 0.002
Ventilation (vs. #24 h)
24–48 h 1.49 (1.04–2.14) 0.03
>48 h 2.45 (1.66–3.63) <0.001
Hyperglycemia (yes/no) 1.32 (1.01–1.73) 0.04
PRBC (unit) 0.03
LVAD/Tx 0.99 (0.89–1.11)
No LVAD/Tx 1.13 (1.07–1.20)
*Model adjusted for baseline risk factors depicted in Table 4.
CEPH ¼ cephalosporin; PRBC ¼ packed red blood cells; other abbreviations as in
Tables 1 and 4.
CENTRAL ILLUSTRATION Infection Risk Factors and SCIP Measure Compliance
Hyperglycemic episode is >180 mg/dl. The top panel was adjusted for baseline patient
and procedure risk factors. ABx ¼ antibiotics; CEPH ¼ cephalosporin; LVAD/Tx ¼ left
ventricular assist device or transplant surgery; PRBC ¼ packed red blood cells;
SCIP ¼ Surgical Care Improvement Project; Vanco ¼ vancomycin.
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378however, only 41% (2,126) of patients received the
recommended prophylactic antibiotics for 48 h after
surgery end time. The ﬁrst post-operative glucose
level was #200 mg/dl in 93% (4,779) of patients,
another SCIP measure. Moreover, 43% (2,228) of
patients had a hyperglycemic episode in the ﬁrst
48 h after surgery but prior to ﬁrst infection. Slightly
more than 20% (1,070) of patients received me-
chanical ventilation for over 24 h after surgery
prior to ﬁrst infection. There was no variation in
use of intra-operative urinary catheters, head of
bed elevation, and secretion management post-
operatively.
Table 6 identiﬁes management practices associ-
ated with risk of major infection, adjusted for base-
line risk factors (Central Illustration). Perioperative
prophylaxis with second-generation cephalosporins
(cefuroxime, cefoxitin,  concomitant vancomycin)
was associated with a 30% reduction in major infec-
tion (hazard ratio [HR]: 0.70; 95% conﬁdence interval
[CI]: 0.52 to 0.94). Second-generation cephalosporins
were associated with decreasing both the risk of a
broad range of Gram-positive (HR: 0.43; 95% CI: 0.24
to 0.76) and Gram-negative (HR: 0.51; 95% CI: 0.32 to
0.83) infections, without signiﬁcantly affecting the
risk of C. difﬁcile colitis. HRs between shorter (0 to
24 h) and longer duration (24 to 48 h) of antibiotic
prophylaxis were similar, but prophylaxis over 48 h
was associated with a near doubling of major infec-
tion risk (HR: 1.92; 95% CI: 1.28 to 2.88). Prolonged
prophylaxis (>48 h) was associated with a 6-fold
increased risk for C. difﬁcile colitis (HR: 6.31; 95%
CI: 2.86 to 14.00). There was a signiﬁcant but differ-
ential effect of transfusion by surgery type (p ¼ 0.03);
the risk of infection was unchanged for LVAD/
transplant patients (HR: 0.99; 95% CI: 0.89 to 1.11),
but red blood cells (RBCs) were associated with
increased risk for all other surgical patients (HR: 1.13;
95% CI: 1.07 to 1.20). Having a hyperglycemic
episode was associated with a 30% increased infec-
tion risk (HR: 1.32; 95% CI: 1.01 to 1.73). Compared
with post-operative ventilation less than 24 h, intu-
bation time of 24 to 48 h was associated with a 50%
(HR: 1.49; 95% CI: 1.04 to 2.14) increased risk of
major infection, and ventilation exceeding 48 h with
a more than 2-fold higher risk (HR: 2.45; 95% CI: 1.66
to 3.63). Although signiﬁcant in the univariate
analysis, femoral lines, and multiple central lines
were not signiﬁcant in the multivariable analysis,
mainly because they were highly correlated with
ventilator time (e.g., patients having ventilation>48 h
were more than 2.5 times more likely to have mul-
tiple lines compared with ventilation #24 h). Thus,
ventilator time subsumed the fraction of the risk
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FIGURE 1 Mantel Byar Survival Curve
97 deaths occurred over the 65-day post-surgery follow-up
period.
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379imparted by multiple central lines and remained in the
model.
MORTALITY AND READMISSIONS. Figure 1 depicts
survival stratiﬁed by presence of a major infection.
Major infection had a substantial effect on survival
(HR: 10.02; 95% CI: 6.12 to 16.39), as also did higher
creatinine (HR: 1.17; 95% CI: 1.06 to 1.29), heart
failure (HR: 2.01; 95% CI: 1.34 to 3.00), diabetes
(HR: 1.65; 95% CI: 1.08 to 2.51), and older age (HR:
1.04; 95% CI: 1.02 to 1.06) (Online Table 4). Mor-
tality risk for men was half that of women (HR:
0.49; 95% CI: 0.33 to 0.72). The 65-day mortality
rate for infected patients was 5% and 0.7% for
noninfected patients. The 30-day readmission rate
was 14%, while the overall readmission rate in this
cohort was 19%. Infections accounted for 16% of all
readmissions.
DISCUSSION
The ﬁndings from this prospective cohort study of
more than 5,000 patients challenge the common
perception that SSIs, particularly deep sternal site
infections, are the most important infections ac-
quired by patients undergoing cardiac surgery.
Instead, we found that pneumonia, bloodstream in-
fections, and C. difﬁcile colitis accounted for 79% of
all major post-operative infections. Moreover, these
major infections occurred later than expected, with
45% becoming evident only after hospital discharge.
These ﬁndings are particularly important given the
prevalence of infections in this population (12% of
patients experienced infections, with 4.6% beingmajor), the high mortality risk (10-fold) for major
infections, and their impact on readmissions.
To assess QI strategies, we examined baseline
predictors for the full range of cardiac surgery pro-
cedures, including the nature of the procedure itself.
Patient- and procedure-related factors associated
with infection risk are similar to those found in
studies of infections after CABG and in ICU patients
(3,12). Contrary to previous observations, this study
did not ﬁnd that obesity, diabetes, or urgent surgery
were independent risk factors for infection in the
multivariable analysis (4,12).
Several management practices were associated
with post-operative infection risk, including the type
and duration of antibiotic prophylaxis. The Society of
Thoracic Surgeons (STS) guidelines recommend using
a ﬁrst-generation cephalosporin, and if patients are
beta-lactam or penicillin allergic, using vancomycin
with additional Gram-negative coverage (13,14).
In this study, second-generation cephalosporins
( vancomycin) were more commonly used than ﬁrst-
generation antibiotics and were strongly associated
with reduced infection risk. This is consistent with
our ﬁnding that Gram-negative organisms, which are
better treated by second-generation cephalosporins,
were the largest category of isolates (47%) among
infected patients. Interestingly, we also observed
that this class of antimicrobials was associated with
improved prevention of Gram-positive infections,
with S. aureus as the most common isolate observed.
As per STS and SCIP recommendations, 86% of pa-
tients received prophylactic antibiotics an hour
before skin incision (except for vancomycin). The
median time for antibiotic administration in patients
receiving “out-of-window” care was 74 min. This
small difference in start time may explain the lack of
difference in occurrence of infection. Both STS and
SCIP recommend 48 h of prophylactic antibiotics
post-surgery (14), which was met in only 41% of pa-
tients. We found no difference in HRs for short-
duration (24 h) versus longer duration (48 h) of
antibiotic prophylaxis, whereas >48 h was associated
with increased risk. Two recent meta-analyses
favored prophylaxis prolongation up to 48 h post-
operatively in preventing SSIs, but no deﬁnitive
conclusions could be drawn given differences in
outcome deﬁnitions, antibiotic regimens and likely
bias in the published trials (15,16). A randomized trial
is needed to evaluate the optimal duration of pro-
phylaxis in preventing not only SSIs, but also a
broader range of infections, such as C. difﬁcile, which
increases substantially with longer antimicrobial
prophylaxis and raises concerns about the ever-
present threat of microbial resistance.
Gelijns et al. J A C C V O L . 6 4 , N O . 4 , 2 0 1 4
Major Cardiac Surgery Infections J U L Y 2 9 , 2 0 1 4 : 3 7 2 – 8 1
380RBCs were transfused in 48% of patients. The
infection risk associated with RBC transfusion was
dose-dependent, with a 13% increase in infection risk
for each additional unit (except for LVAD/transplant
patients). This argues for decreasing the amount of
blood transfused, but the risks and beneﬁts of trans-
fusion must be weighed against the risks of anemia.
Several practices may reduce the need for trans-
fusion, including cell salvage, small priming volumes,
vacuum-assisted venous return with rapid autolo-
gous priming, ultraﬁltration, and pre-operative mea-
sures to elevate hematocrit (6).
Recent Centers for Disease Control and Preven-
tion data document a 54% decrease in bloodstream
infections in ICUs of teaching hospitals, but as the
second most common infection in our study, they
remain high in cardiac surgery patients (17). Efforts
to decrease such infection include full barrier pre-
cautions for central lines, avoiding the femoral site
and removing unnecessary central venous catheters.
In our univariate analysis, multiple central lines,
and femoral lines increased major infection risk,
supporting the practice of minimizing the duration
of their use. But multiple lines correlated strongly
with prolonged ventilator time, which remained in
the multivariable model. Our study quantiﬁed the
risk for longer ventilation times; even a modest
prolongation of ventilation (24 vs. 48 h) was asso-
ciated with a 50% increase in risk of infection,
arguing for terminating mechanical ventilation as
soon as possible.
Stress hyperglycemia, deﬁned as 1 or more blood
sugar measurements above 180 mg/dl during the
ﬁrst 48 h post-operatively, was associated with a
30% risk of major infection. Hyperglycemia has been
found in the literature to be a predictor of mortality
and major morbidity, and averting hyperglycemia
(as assessed by the ﬁrst 6.00 AM blood sugar after
surgery) has been the focus of national QI efforts
(18). Yet, a substantial number of our patients still
experienced hyperglycemic episodes as well as hy-
poglycemic episodes, which argues for the adoption
of novel approaches, such as glycemic control man-
agement systems that track blood sugars and pro-
vide the therapeutic guidance that would reduce
blood sugar variations through software-based
algorithms.
Controversy surrounds the value of routine
screening for S. aureus nasal carriage and nasal
decontamination in surgical patients, with the
strongest evidence for its use in patients undergoing
cardiac surgery or receiving an implant (19, 20). In our
study, only half of the CTSN sites used nasal decon-
tamination, and this practice was not associated withreduced infection risk. Further trials are needed to
substantiate the beneﬁts in cardiac surgery.
STUDY LIMITATIONS. Its purpose was to quantify the
burden of all serious infections in the post-operative
period and identify a constellation of management
practices associated with reduced infection risk,
which does not easily lend itself to a randomized
design and limits our ability to measure the inde-
pendent impact of speciﬁc interventions for speciﬁc
infections. We were careful to take into consideration
the timing of management practices and incorporated
in the analysis only those practices that were used
prior to the onset of infection (except transfusions,
the timing of which was sometimes unavailable).
Finally, infection and mortality events occurred later
than anticipated, and a longer follow-up period may
have identiﬁed further events.
In this unique prospective cohort study of infec-
tion after all types of cardiac surgery, major in-
fections were common and dramatically increased
mortality. Prolonged ventilation and transfusion
were strongly associated with adverse outcomes,
while the use of second-generation cephalosporins
was associated with improved outcomes. Given the
variation in practices, our ﬁndings offer opportu-
nities for improving patient outcomes and speak to
policy incentives to avert infections, including
reimbursement penalties for preventable infections,
public reporting of adherence to SCIP measures, and
incorporation of hospital-speciﬁc infection rates in
ranking systems to inform consumer choice (21,22).
Interestingly, our study demonstrated reasonably
high adherence to SCIP measures and STS guide-
lines, but deviation from several measures seemed
to have little impact on infection outcomes. Others
have made similar observations using administrative
datasets (23). These ﬁndings suggest that—in a dy-
namic environment of evolving interventions, pa-
tients and offending microbes—we need to create
an infrastructure for frequent re-evaluation of
the incidence of healthcare-acquired infections,
effectiveness of management practices, and ade-
quacy of management guidelines. This is especially
critical in an era that emphasizes early post-operative
discharge and reduction of preventable read-
missions, which are both heavily inﬂuenced by
infection.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Within
2 months after cardiac surgery, 5% of patients experi-
enced major infections, nearly half of which were not
identiﬁed until after hospital discharge. The most
frequent were pneumonia (41%), bloodstream infections
(20%), and C. difﬁcile colitis (17%).
COMPETENCY IN MEDICAL KNOWLEDGE 2:
Patients whose course post-cardiac surgery was compli-
cated by major infections experienced a mortality rate
10 times greater than those who did not.
COMPETENCY IN PATIENT CARE: Administration of
prophylactic antibiotic medication for more than 48 h,
routine mechanical ventilation for more than 48 h, stress-
induced hyperglycemia, and transfusions of blood prod-
ucts are associated with an increased risk of infection
after cardiac surgery.
TRANSLATIONAL OUTLOOK: Prospective clinical tri-
als are needed to deﬁne the optimum type and duration
of antibiotic prophylaxis and thresholds for transfusion of
blood products and assess the efﬁcacy of these strategies
to reduce the risk of infection in patients undergoing
cardiac surgery.
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